Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod versus methyl aminolevulinate photodynamic therapy for actinic keratosis in organ transplant recipients
2010-024623-24Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2011
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imiquimod and methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Clinical complete remission rate at 4 weeks. Started Nov 2011; status: completed.
02
Drugs
imiquimodmethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2010-024623-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024623-24.